Nature Reviews Drug Discovery Submission Guide

Source: Clarivate JCR 2024, Nature Portfolio editorial disclosures (accessed April 2026).

Source: NRDD author guidelines.

Use this page when deciding:

• whether the proposed Review has a synthesis argument strong enough for NRDD

• whether the author team has sustained authority in the drug-discovery subfield

• whether topic timing is right for an NRDD presubmission inquiry

• a clear synthesis argument or organizing framework

• author authority with primary-research evidence in the drug-discovery subfield

• topic-timing case (no recent NRDD overlap)

• direct implications for pharma R&D or translational practice

• a 1-2 page outline with author authority statement

• Topic recently covered in NRDD or adjacent Nature Reviews journals.

• Author standing in adjacent rather than central drug-discovery research.

• Scope framed as comprehensive survey rather than synthesis.

• Pharma R&D relevance is peripheral.

NRDD is among the highest-impact journals globally and operates a strict commissioning model.

Synthesis-first standard: the journal differentiates from Drug Discovery Today (broader coverage) and Nature Reviews Drug Targets (more target-focused) by demanding an organizing argument, not exhaustive coverage.

The presubmission-inquiry filter: NRDD declines ~85-90% of unsolicited inquiries before invitation.

Authority expectation: editors weigh sustained primary-research records heavily.

The strongest NRDD inquiry letters establish:

• the synthesis argument in one sentence

• the author authority with primary-research record

• the topic-timing case

• the pharma R&D relevance

Nature Reviews Drug Discovery requires these at the presubmission-inquiry stage:

• Cover letter explicitly establishing the synthesis argument and broad pharma R&D relevance (the journal weights breadth heavily; subfield-internal proposals rarely advance)

• 200-word abstract describing the proposed Review's core argument and scope

• Brief description of main article sections (typically 5-8 section headings with 1-2 sentence summaries each)

• List of key references the Review will synthesize (typically 30-60 references, demonstrating sustained author authority in the drug-discovery subfield)

• List of authors and their affiliations with credentials showing sustained drug-discovery expertise

• Statement of competing interests for all authors (especially pharmaceutical industry consulting, patent holdings, and equity positions)

• Confirmation that no recent NRDD Review has covered the proposed topic (the journal avoids near-duplicate Reviews)

At the invited full-Review stage, additional artifacts are required:

• Cover letter referencing the invitation

• Full manuscript per the Nature Reviews format guidelines

• Data availability statement covering any quantitative meta-analysis data or systematic review search records

• Code availability statement for any computational analyses

• Ethics statement for any human-subject or animal-research content discussed

• Informed consent statement where relevant

• CRediT author contributions statement

• Four or more suggested reviewers with no recent collaboration history

For Nature Reviews Drug Discovery submissions, the most common presubmission-inquiry rejection is timing collision with recent NRDD coverage. The journal explicitly avoids near-duplicate Reviews; proposals on topics where NRDD published a related Review within the prior 12-24 months commonly receive a Week-1 decline regardless of the synopsis quality.

For Nature Reviews Drug Discovery submissions, the editorial timeline runs through four phases shaped by the journal's commissioning-and-inquiry workflow.

Day 0 to 14: Presubmission inquiry submission and editor evaluation

Authors submit the synopsis through MTS. Springer Nature editors evaluate the proposal against the journal's selectivity bar (synthesis argument, broad pharma R&D relevance, sustained author authority, timing). The handling Editor assignment lands within 14 days. The functional acceptance rate at the presubmission-inquiry stage runs approximately 10-15%; the most common Week 0-2 decline reason in our review work is timing collision with recent NRDD coverage.

Day 14 to 60: Invitation decision and Review preparation start

Invited authors typically have 3-4 months to deliver the full commissioned Review. The journal supports invited authors with editorial guidance during this period. Once invited, completion-and-publication rates are high; the editorial filter has already done most of its work at the presubmission-inquiry stage.

Week 8 to 24: Full Review drafting and submission

Invited authors deliver the full Review (typically 10,000-15,000 words for major Reviews) covering the proposed synthesis argument with deeper section content than the synopsis indicated. The full Review then enters formal peer review.

Week 24 to 52: Peer review, revision, and production

Nature Reviews Drug Discovery uses rigorous external peer review with several experts in the drug-discovery domain. Major revision is standard at first decision. Revision rounds typically settle at 2 (rarely 3 for accepted Reviews). Total submission-to-publication: 9-15 months for accepted Reviews once the full-Review stage begins.

• the synthesis argument is clear in one sentence

• the author team has sustained primary-research record in the drug-discovery subfield

• the topic-timing case is strong

• pharma R&D relevance is direct

• Is Nature Reviews Drug Discovery a good journal?

Before inquiring, run your proposal through a Nature Reviews Drug Discovery presubmission readiness check.

Read the public instructions for mechanics, then pressure-test the package the way an editor will see it. The review tells you whether your paper clears the Nature Reviews Drug Discovery fit check before upload, especially around topic-timing collision with recent NRDD coverage, author standing in adjacent rather than central drug-discovery research, and synthesis-versus-survey framing problems. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across Manusights submission reviews for Review proposals targeting NRDD, three patterns generate the most consistent inquiry declines.

Manusights pre-submission pattern analysis shows many NRDD declines trace to topic-timing collision with recent NRDD coverage. The same pattern analysis often finds these cases involve author-authority gaps. A related pattern is that these cases often arise from synthesis-versus-survey framing problems.

Topic-timing collision with recent NRDD coverage

NRDD editors check the journal's recent issues. We observe inquiries proposing topics overlapping NRDD coverage in the prior 3-5 years routinely declined unless a clearly distinct angle is articulated.

Check topic timing collision with recent nrdd coverage before submitting to Nature Reviews Drug Discovery →

Author standing in adjacent rather than central drug-discovery research

NRDD editors weigh sustained primary-research records heavily. We see inquiries from authors with primary research in adjacent pharmaceutical or biological subfields routinely declined unless the drug-discovery connection is direct.

Check author standing in adjacent rather than central drug discovery research before submitting to Nature Reviews Drug Discovery →

Synthesis-versus-survey framing problems

NRDD specifically expects a synthesis argument, not comprehensive coverage. We find that proposals framed as "comprehensive review of topic]" routinely declined; proposals framed around an organizing argument receive better editorial traction. A [NRDD presubmission readiness check can identify whether the inquiry case is strong.

Clarivate JCR 2024 bibliometric data places NRDD among the highest-impact journals globally.

Check synthesis versus survey framing problems before submitting to Nature Reviews Drug Discovery →

Before the reviewer-invitation stage, read the Nature Reviews Drug Discovery package against the same risks this guide flags in the Manusights section. The practical question is whether the abstract, cover letter, figures or tables, methods, reporting statements, supplementary files, and references all make the journal choice obvious.

• If the abstract still points toward topic-timing collision with recent NRDD coverage, revise the central claim before upload.

• If the evidence package leaves author standing in adjacent rather than central drug-discovery research, strengthen the methods, controls, figures, or supplementary material rather than expecting reviewers to infer it.

• If the cover letter cannot resolve synthesis-versus-survey framing problems, compare the target journal against the adjacent venues named above before submitting.

In pre-inquiry diagnostic work for high-impact commissioning Review journals, we consistently see four signals that distinguish strong proposals from weak ones. First, the proposed topic must align with what NRDD editors are publicly signaling as priority directions through recent editorials, conference participation, and Springer Nature thematic announcements.

Second, the author CV should show 10+ primary-research papers in the exact drug-discovery subfield over the prior decade, not just adjacent-area credentials. Third, the proposal should differentiate sharply from Reviews published in NRDD or adjacent Nature Reviews journals in the prior 5 years; proposals that overlap a recent piece's table of contents are declined on that basis alone.

Fourth, the proposal should be framed in terms of what the synthesis will reorganize or argue, not as comprehensive coverage of recent papers.

For Nature Reviews Drug Discovery-targeted manuscripts, beyond the rubric checks, three pre-inquiry diagnostic patterns recur most often in the proposals we review for NRDD. First, inquiry letters that begin with topic-context paragraphs rather than the synthesis argument lose force in editorial scanning. We recommend the inquiry's opening sentence state the synthesis argument or contrarian thesis; everything else is supporting context.

Second, inquiries where the author authority section uses generic language (we have published in this area) without specifying paper count, journal venues, and specific subfield contributions are flagged at desk for insufficient authority detail. Editors at NRDD expect the authority statement to establish that this team is positioned to write the authoritative Review on this topic.

Third, inquiries that lack engagement with NRDD's recent issues are at risk of being told the proposal doesn't fit the publication conversation. We recommend inquiry authors review NRDD's last 12-18 months of issues before drafting and explicitly cite at least 2-3 Reviews from those issues as positioning context.